Stock Analiz

MRK vs AZN stock comparison

Merck & Co. vs. Astrazeneca · data as of November 13, 2026

Merck & Co. (MRK) has a market value of about $364.3B, Astrazeneca (AZN) about $286.0B. Over their latest twelve months Merck & Co. had revenue of $67.4B and Astrazeneca $62.4B.

Both score 2.8 out of 5 on our five checks.

By area, the stronger company is Astrazeneca on value; Merck & Co. on track record; Astrazeneca on financial health; Merck & Co. on shareholder returns.

Astrazeneca is cheaper on earnings (P/E 26.1 vs. 150.8).

Merck & Co. leads on 8 of the compared lines and Astrazeneca on 15.

Side by side

MRKAZN
Size and price
Market cap$364.3B$286.0B
Share price$147.76$184.45
Score
Overall score (of 5)2.82.8
Value01
Future growth22
Track record54
Financial health23
Shareholder returns54
Valuation
P/E (TTM)150.826.1
Forward P/E17.616.5
Price / free cash flow24.746.9
Price / sales5.44.6
EV / EBITDA32.514.7
PEG7.101.20
DCF value vs. price−31%−38%
Business
Revenue$67.4B$62.4B
Net income$2.5B$11.0B
Free cash flow$14.7B$6.1B
Net margin3.6%17.7%
Gross margin (5-yr avg.)73.4%76.8%
ROIC (5-yr avg.)16.3%8.4%
Growth
Revenue growth (1 yr)1.3%8.6%
Revenue growth (5 yrs, per year)9.4%17.2%
EPS growth (5 yrs, per year)21.2%21.8%
Balance sheet and payouts
Net cash (cash minus debt)-$44.1B-$26.0B
Dividend yield2.30%1.74%
Shareholder yield3.7%1.9%
Analysts
Upside to average target+9%+13%
Consensus ratingBuyBuy

Highlighted = the better figure on that line. Revenue, net income and free cash flow: MRK TTM to September 30, 2026, AZN TTM to September 30, 2026. Not investment advice.

Frequently asked questions

Which is the better stock, Merck & Co. or Astrazeneca?

We do not give buy or sell advice. On our five checks (value, growth, track record, financial health and shareholder returns) Merck & Co. scores 2.8 out of 5 and Astrazeneca 2.8; the table shows where each one is stronger.

Is Merck & Co. cheaper than Astrazeneca?

On trailing earnings, Astrazeneca trades at a P/E of 26.1 and Merck & Co. at 150.8, so Astrazeneca is cheaper by this measure. A lower P/E can also reflect slower expected growth.

Which grows faster, Merck & Co. or Astrazeneca?

Over five years Astrazeneca grew revenue about 17.2% a year and Merck & Co. about 9.4% a year.

Which pays a higher dividend?

Merck & Co. yields 2.30% and Astrazeneca 1.74%.

Full Merck & Co. analysis → Full Astrazeneca analysis →

More comparisons

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.